Malignant Tumour
Conditions
Brief summary
As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.
Detailed description
The boom in radiopharmaceuticals continues to persist, including their driving effects in the field of immunotherapy. CD73 (ecto-5'-nucleotidase), a key purine metabolic enzyme, catalyzes the conversion of extracellular nucleotides to adenosine, promoting tumor immune evasion and unfavorable clinical outcomes. Notably, CD73 is highly expressed in 74.3% of breast cancer cases, with its prevalence exceeding 45% in liver, gastric, colorectal, and ovarian cancers. As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. The present study aimed to evaluate the biodistribution, pharmacokinetics, and dosimetry of 68Ga-dPNE, and performed a head-to-head comparison with 18F-FDG PET/CT scans in patients with various cancers.
Interventions
DRUG68Ga-dPNE
Intravenous injection of 68Ga-dPNE. 68Ga-dPNE PET/CT will be used to detect tumors.
DRUG18F-FDG
Intravenous injection of 18F-FDG.18F-FDG PET/CT will be used to detect tumors.
Sponsors
First Affiliated Hospital of Fujian Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
Signed informed consent and be able to follow up.
Exclusion criteria
Pregnant or lactational women; who suffered from severe hepatic and renal insufficiency.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SUV of tumors | Through study completion, an average of 3 months | Compare the SUV of tumors between 68Ga-dPNE PET/CT and 18F-FDG PET/CT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic value | Through study completion, an average of 3 months | Sensitivity and specificity of 68Ga-dPNE in patients with various types of cancer and compare it with 18F-FDG PET/CT. |
Countries
China
Contacts
Primary ContactWeibing Miao, MD
Backup ContactRong Lin, MD
Outcome results
None listed